Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB4
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
The identifier 'MB4' is non-specific and refers to multiple distinct entities in scientific literature. One such entity is a benzamide derivative that has been investigated as a human dihydrofolate reductase (hDHFR) inhibitor, a promising strategy for cancer therapy. This compound has also shown activity against acetylcholinesterase (AChE) and β-secretase (BACE1), suggesting potential applications in neurodegenerative diseases like Alzheimer's. Another distinct compound referred to as MB4 is a pyrogallol-based mitochondria-targeted antioxidant, studied for its potential to delay skin aging and prevent cellular senescence.
- Other names
- Benzamide derivative MB4
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on MB4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB4.